Gland Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Gland Pharma Ltd reported a 1.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 7.6%.
• Its expenses for the quarter were down by 2.4% QoQ and up 1.3% YoY.
• The net profit increased 12.0% QoQ and increased 49.9% YoY.
• The earnings per share (EPS) of Gland Pharma Ltd stood at 13.1 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gland Pharma Ltd is a pharmaceutical company specializing in the production of complex injectables, catering to a wide array of therapeutic categories. The company operates within the pharmaceutical industry, focusing on the manufacture and commercialization of injectable formulations. Gland Pharma is known for its strong emphasis on research and development, aiming to meet stringent regulatory standards across different international markets. As of the latest available data, there are no specific significant recent developments mentioned. However, it is pertinent to note that the pharmaceutical industry is typically characterized by its sensitivity to regulatory approvals and research advancements.

Revenue

The total income for Gland Pharma Ltd in Q1FY26 was ₹1563.15 crores, compared to ₹1579.60 crores in Q4FY25 and ₹1453.14 crores in Q1FY25. This reflects a quarter-over-quarter (QoQ) decrease of 1.0% and a year-over-year (YoY) increase of 7.6%. The decrease in total income on a QoQ basis suggests a slight decline in revenue generation from the previous quarter, while the YoY increase indicates an improvement in revenue compared to the same quarter in the previous year. These metrics provide an insight into the company’s revenue trends over the specified periods.

Profitability

The profitability of Gland Pharma has shown positive trends in the latest quarter. The profit before tax (PBT) for Q1FY26 was ₹312.74 crores, an increase from ₹298.23 crores in Q4FY25 and ₹218.24 crores in Q1FY25, resulting in a QoQ growth of 4.9% and a substantial YoY growth of 43.3%. The tax expense decreased by 8.1% QoQ to ₹97.26 crores, while showing a 30.6% increase YoY. Consequently, the profit after tax (PAT) rose to ₹215.48 crores in Q1FY26 from ₹192.42 crores in Q4FY25 and ₹143.76 crores in the corresponding quarter of the previous year, marking a 12.0% QoQ and 49.9% YoY growth. The earnings per share (EPS) also mirrored this trend, increasing by 12.0% QoQ and 50.6% YoY to reach ₹13.10.

Operating Metrics

The total expenses for Gland Pharma Ltd in Q1FY26 amounted to ₹1250.41 crores, showing a reduction from ₹1281.37 crores in Q4FY25 and a slight increase from ₹1234.89 crores in Q1FY25. This represents a 2.4% decrease QoQ and a 1.3% increase YoY. The decrease in expenses QoQ may indicate effective cost management strategies during the quarter. The company's ability to control its expenses relative to its income contributes to its operational efficiency and profitability. These metrics are essential for evaluating the company's capacity to manage its operational costs in relation to its revenue-generating activities.